Skip to content
Thirty people walk into a hospital in Yokohama. They're all between fifty and eighty, all reporting the kind of slow cognitive slide that shows up in your sixties and gets labelled "mild cognitive impairment" by a doctor who isn't sure what to do about it. They're handed identical-looking white tablets. Twelve a day, every day, for sixteen weeks. Half of them are getting cornstarch and lactose. The other half are getting Hericium erinaceus, lion's mane, dried overnight at sixty degrees and pressed into pills. Real fruiting bodies. Three grams a day. And nobody, not the patients, not the researchers, not the doctors handing out the tablets, knows which is which.
What happens over those sixteen weeks is interesting. What happens after them is the part that should make you pay attention.
The Climb
Eight weeks in, the mushroom group is already scoring higher on memory tests than the placebo group. Not dramatically, but reliably. Twelve weeks in, the gap has widened. By week sixteen, it's wider still.
The headline number, when the trial finally unblinds, is brutal. Thirteen of the fourteen people on lion's mane have shown measurable cognitive improvement from where they started. In the placebo group: one person out of fifteen.
The placebo group's average did creep upward over the trial, which the researchers admitted in print could be a small placebo effect or, more probably, the boring fact that people who take the same memory test five times in a row tend to get marginally better at it. They didn't try to hide that. They just noted, fairly, that whatever drift the placebo group had, the mushroom group's climb was significantly steeper than it.
This much alone would be a respectable result. Most supplement studies stop here. They run their treatment, they tally the favourable numbers, they publish, and the supplement industry quotes the result in marketing copy for the next decade.
The Yokohama researchers did something different. They added a fourth phase.
The Test That Most Supplements Never Pass
Four weeks after the treatment ended, the patients came back to the hospital and took the cognitive test one more time. They had stopped the tablets. Life had carried on. The researchers wanted to see what the gains looked like in the absence of the input.
The mushroom group's scores fell. Significantly. Not all the way back to where they started, but enough that the authors concluded, in print, that "continuous intake is necessary to maintain the effect."
When people took it daily, their memory climbed. When they stopped, it fell.
This is the half of the experiment that most studies don't bother with, and it's also the half that does the most epistemic work. Without it, you can't actually rule out the alternative explanations. Maybe the patients improved because they were enrolled in a trial and felt cared for. Maybe they ate a bit better, or slept a bit more, because they were paying attention to their health. Maybe regression to the mean. Quite possibly placebo. The post-treatment phase rules these out. None of those alternatives would explain why the effect reverses the moment you take the input away. The tablets were doing something. When the tablets stopped, the something stopped too.
It also tells you something about durability. Whatever lion's mane was doing, it wasn't permanent rewiring. It was support, contingent on continuation. That's not a flashy finding. It's a useful one.
The Mechanism, Probably
To understand why this might work at all, you have to go back further. In 1986, Rita Levi-Montalcini and Stanley Cohen won the Nobel Prize in Physiology or Medicine for the discovery of nerve growth factor, NGF. The Nobel committee called it "extremely potent" for nerve cells. NGF is what your brain uses to maintain its own infrastructure, to keep neurons alive, to keep the wiring intact. Less of it over time is one of the things that goes wrong in cognitive decline. The trouble is that NGF itself can't be turned into a medicine, because the protein is too large to cross the blood-brain barrier. So pharmacology started looking instead for smaller compounds that might persuade the brain to make more of its own.
Five years after the Nobel, in 1991, a team led by the Japanese chemist Hirokazu Kawagishi found some. Compounds called hericenones, isolated from the fruiting body of lion's mane, stimulated NGF synthesis in cultured cells. Three years later, the same team found a separate class, called erinacines, in the mushroom's mycelium. Both groups of compounds did the same thing through different chemistry. Other research groups have replicated and extended the work in the decades since.
The Yokohama authors were openly modest about whether their clinical results were driven by this mechanism specifically. The hericenone studies, they pointed out, were mostly in rodent cells, and it remained an open question whether the active compounds reliably reach the human brain at all. Thirty people is a small sample. You can't prove the chain.
But the chain of evidence, taken together, is suggestive in a way that very few supplement-trial chains are. A known biological pathway. A plausible mechanism for influencing it. And a clinical trial showing the kind of dose-on-dose-off effect you'd expect if the pathway were actually being engaged.
Which brings us to the practical question hidden inside all of this.
What You Should Expect From a Mushroom
The supplement industry sells a particular fantasy: that the right capsule, taken at the right moment, produces a noticeable effect you can feel. A switch flipping. A lift. A clarity. Most products in this space are implicitly or explicitly marketed against that promise, because it sets up a satisfying first experience and an unsatisfying second one, and conveniently re-creates the conditions for a follow-up purchase three months later when the first effect has faded.
Lion's mane doesn't work this way, and neither, honestly, does most of what's worth taking. The Yokohama data is telling you something specific. The improvement was incremental. It built over weeks. It required daily input. It showed up on cognitive tests before it would have shown up in how anyone felt. And it depended, structurally, on continuation. The moment you stopped feeding the system, the system stopped responding.
This is not a marketing-friendly model. You can't sell a "feel it the first day" promise out of it. What you can do is tell the truth: this is a substrate, not a stimulant. It supports the slow biological processes that keep your brain in repair. The effects compound by the day and decay by the day. You don't take it for the moment. You take it for the trajectory.
The kind of thing, in other words, you only notice when it's gone.
